Studies have shown that down-regulating NOD-like receptor (NLR) X1 (NLRX1) can inhibit glycolysis, enhance fat oxidation and reduce hepatic steatosis (Kors et al., 2018). Here, NLRX1 is linked to fatty liver disease.